{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-055083","form_type":"8-K","ticker":"VTGN","cik":"0001411685","company_name":"Vistagen Therapeutics, Inc.","filed_at":"2025-12-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.343614+00:00","generated_at":"2026-05-16T15:04:56.388101+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Vistagen appoints Nick Tressler as CFO effective Dec 1, 2025","bullets":["Nick Tressler named CFO & Treasurer, effective Dec 1, 2025; succeeds Shawn Singh as interim PFO.","Starting annual base salary of $450,000; signing bonus of $50,000; target cash bonus of 45% of base.","Granted inducement option for 150,000 shares at $4.43 per share; vests over 4 years with 1-yr cliff.","Tressler brings 20+ years life sciences finance experience; most recently CFO at DYNEX Technologies.","Shawn Singh will no longer serve as interim principal financial and accounting officer."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-055083","json":"https://secwatch.observer/filing/0001628280-25-055083.json","markdown":"https://secwatch.observer/filing/0001628280-25-055083.md","text":"https://secwatch.observer/filing/0001628280-25-055083.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411685/000162828025055083/0001628280-25-055083-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411685/000162828025055083/vtgn-20251128.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T15:04:56.388101+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}